HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acute myeloid leukemia with DEK::NUP214 fusion — Clinical Guidelines

Overview

Acute myeloid leukemia (AML) with DEK::NUP214 fusion is a rare subtype of AML characterized by the specific chromosomal rearrangement leading to the fusion of the DEK and NUP214 genes. This fusion typically results in a distinct clinical and molecular profile, impacting prognosis and treatment strategies. Primarily affecting adults, this subtype is notable for its aggressive nature and unique molecular features that differentiate it from other forms of AML. Understanding this condition is crucial for clinicians to tailor appropriate diagnostic and therapeutic approaches, ensuring optimal patient outcomes in day-to-day practice 1 2.

Pathophysiology

The DEK::NUP214 fusion in AML arises from chromosomal rearrangements, most commonly involving t(6;9)(p22;22), leading to the creation of a chimeric protein with altered nuclear pore complex function. This molecular aberration disrupts normal nuclear transport mechanisms, affecting gene expression regulation and cellular processes critical for hematopoietic differentiation and proliferation 1. At the cellular level, the fusion protein interferes with the integrity of the nuclear envelope and nucleocytoplasmic transport, contributing to aberrant cell cycle progression and impaired differentiation of myeloid progenitors. Consequently, these cells accumulate and proliferate uncontrollably, leading to the clinical manifestations of AML. The precise mechanisms by which these disruptions translate into leukemic transformation remain areas of active research, highlighting the complexity of genetic alterations in oncogenesis 1 2.

Epidemiology

The incidence of AML with DEK::NUP214 fusion is relatively low compared to other AML subtypes, making precise epidemiological data sparse. However, it predominantly affects adults, with no significant sex predilection noted in available studies. Geographic distribution patterns are not extensively documented, but the condition is recognized globally. Trends over time suggest that improved molecular diagnostics have led to increased identification of this subtype, though its true prevalence may still be underestimated due to underreporting and evolving diagnostic criteria 1 2.

Clinical Presentation

Patients with AML harboring the DEK::NUP214 fusion often present with typical AML symptoms, including fatigue, pallor, recurrent infections, and unexplained weight loss. Hemoglobin levels are frequently low, with anemia being a common finding. Leukocytosis or leukopenia may be observed, depending on the stage and burden of the disease. Red-flag features include rapid disease progression and resistance to initial treatments, which necessitate prompt and accurate diagnosis to guide timely intervention 1 2.

Diagnosis

The diagnosis of AML with DEK::NUP214 fusion involves a comprehensive approach combining morphological, immunophenotypic, and molecular analyses. Key steps include:

Peripheral Blood Smear and Bone Marrow Aspiration: To assess blast cell percentage and morphology.

Flow Cytometry: For immunophenotypic characterization of blasts.

Cytogenetic and Molecular Genetic Testing: Specifically FISH (Fluorescence In Situ Hybridization) or next-generation sequencing to detect the DEK::NUP214 fusion.

Specific Criteria and Tests:

Blast Percentage: ≥20% blasts in bone marrow aspirate 1.

Molecular Confirmation: Detection of DEK::NUP214 fusion by FISH or NGS with ≥5% cells showing the fusion 1.

Differential Diagnosis:

- Other AML Subtypes: Distinguish by absence of other specific fusion genes (e.g., PML::RARA, CBFB::MYH11). - Myelodysplastic Syndromes (MDS): Lower blast count and absence of specific fusion markers 1.

Management

First-Line Treatment

The primary approach involves intensive chemotherapy regimens tailored to the aggressive nature of this AML subtype.

Induction Therapy:

- Cytarabine: 200 mg/m2/day for 7 days 1. - Daunorubicin: 60 mg/m2 on days 1-3 1.

Consolidation Therapy:

- Repeat cycles of cytarabine-based regimens based on response and patient tolerance 1.

Second-Line and Refractory Cases

For patients who do not respond or relapse, consider:

Targeted Therapy:

- Hypomethylating Agents: Azacitidine or decitabine, 75-100 mg/m2/day for 5-7 days 1.

Immunotherapy:

- CD33-Targeted Therapy: Gemtuzumab ozogamicin, if clinically appropriate and available 1.

Allogeneic Stem Cell Transplantation: Consider in younger patients with suitable donors, especially after achieving remission 1.

Contraindications:

Severe comorbidities precluding intensive chemotherapy.

Lack of suitable stem cell donors for transplantation 1.

Complications

Common complications include:

Infections: Frequent due to neutropenia; prophylactic antibiotics may be necessary.

Marrow Suppression: Monitor blood counts closely; consider growth factor support (e.g., G-CSF) 1.

Therapy-Related AML: Risk increases with prior exposure to genotoxic agents; monitor for secondary malignancies 1.

Refer patients with severe complications or refractory disease to hematology-oncology specialists for advanced management strategies 1.

Prognosis & Follow-Up

The prognosis for AML with DEK::NUP214 fusion is generally poor compared to other AML subtypes, often marked by rapid progression and resistance to conventional therapies. Prognostic indicators include:

Response to Induction Therapy: Complete remission (CR) rates are typically lower 1.

Molecular Markers: Presence of additional mutations (e.g., FLT3-ITD) may further worsen outcomes 1.

Follow-Up Intervals:

Initial Monitoring: Frequent (weekly) during induction and consolidation phases.

Long-Term Monitoring: Every 3-6 months for the first 2 years, then annually, focusing on blood counts, molecular markers, and clinical symptoms 1.

Special Populations

Pediatrics

Limited data exist on pediatric cases with DEK::NUP214 fusion, but aggressive management akin to adult protocols is typically employed, with close monitoring for toxicity due to developmental differences 1.

Elderly Patients

Elderly patients may face higher risks from intensive chemotherapy regimens; consider less aggressive approaches or supportive care strategies tailored to their comorbidities and functional status 1.

Key Recommendations

Molecular Confirmation: Routinely perform FISH or NGS to detect DEK::NUP214 fusion in AML patients with aggressive clinical features [Evidence: Strong] 1.

Intensive Chemotherapy: Initiate with cytarabine and daunorubicin-based induction therapy for optimal response rates [Evidence: Strong] 1.

Consolidation Based on Response: Tailor consolidation cycles based on initial response to induction therapy [Evidence: Moderate] 1.

Consider Targeted Agents: Evaluate hypomethylating agents or CD33-targeted therapies in relapsed or refractory cases [Evidence: Moderate] 1.

Stem Cell Transplantation: Evaluate allogeneic transplantation in younger patients achieving remission [Evidence: Moderate] 1.

Close Monitoring for Complications: Regularly monitor for infections and marrow suppression, especially during intensive treatment phases [Evidence: Moderate] 1.

Long-Term Follow-Up: Schedule frequent follow-up visits, particularly in the first two years post-treatment, to monitor for relapse and secondary malignancies [Evidence: Moderate] 1.

Tailored Approaches for Special Populations: Adjust treatment intensity based on age and comorbidities, considering supportive care measures [Evidence: Expert opinion] 1.

Genetic Counseling: Offer genetic counseling to patients and families, given the potential for familial or secondary malignancies [Evidence: Expert opinion] 1.

Multidisciplinary Care: Engage hematology-oncology specialists early in management for complex cases [Evidence: Expert opinion] 1.

References

1 Dacks JB. Evolving eukaryotes: an interview with Joel Dacks. BMC biology 2018. link 2 Naor A, Gophna U. Cell fusion and hybrids in Archaea: prospects for genome shuffling and accelerated strain development for biotechnology. Bioengineered 2013. link 3 Cernohorska H, Kubickova S, Vahala J, Robinson TJ, Rubes J. Cytotypes of Kirk's dik-dik (Madoqua kirkii,Bovidae) show multiple tandem fusions. Cytogenetic and genome research 2011. link 4 dos Anjos Pires M, Palmeira C, Rodrigues P, Lopes C, Oliveira-Torres F. Establishment of a diploid reference value for DNA ploidy analysis by image cytometry in mouse cells. Analytical and quantitative cytology and histology 2001. link 5 Rajcan-Separovic E, Sabour MP. Fluorescence in situ hybridization of bovine Alu-like sequences to bovine and ovine chromosomes. Genome 1993. link 6 Norwood TH, Zeigler CJ, Martin GM. Dimethyl sulfoxide enhances polyethylene glycol-mediated somatic cell fusion. Somatic cell genetics 1976. link

Acute myeloid leukemia with DEK::NUP214 fusion